论文部分内容阅读
目的 :研究经阴道用甲硝唑在早孕绒毛和羊水中的药物浓度。方法 :随机选择自愿终止妊娠的妇女 41名。其中孕 8周内妇女 2 1名 ,孕 12周左右妇女 2 0名。两种孕周妇女再分两组 ,一组为治疗组 ,阴道用甲硝唑 ;另一组为对照组 ,口服甲硝唑。结果 :经阴道用药组绒毛中甲硝唑平均浓度为 0 .0 6 8μg·ml-1;口服用药组绒毛中平均浓度为 0 .82 3μg·ml-1,两者差异有显著性 (P <0 .0 1)。经阴道用药组羊水中甲硝唑平均浓度为 0 .6 38μg·ml-1,口服组羊水中平均浓度 2 .496 μg·ml-1,两者差异有显著性 (P <0 .0 1) ;经阴道用药组血清中甲硝唑含量 (0 .15 1μg·ml-1)显著低于口服用药组 (2 .414μg·ml-1) (P <0 .0 1)。结论 :结果表明 ,早孕期妇女经阴道用甲硝唑要比口服甲硝唑安全。
OBJECTIVE: To study the drug concentration of metronidazole in vagina and amniotic fluid in early pregnancy. Methods: 41 women who voluntarily terminated pregnancy were randomly selected. Among them, 21 were pregnant in 8 weeks and 20 were pregnant in 12 weeks. Two gestational age women were divided into two groups, one for the treatment group, vaginal metronidazole; the other for the control group, oral metronidazole. Results: The mean concentration of metronidazole in vaginal administration group was 0.068 μg · ml-1, while the average concentration of metronidazole in oral administration group was 0.82 3 μg · ml-1, the difference was significant (P < 0 .0 1). The average concentration of metronidazole in amniotic fluid in vaginal drug group was 0.638μg · ml-1, and the average concentration of amniotic fluid in oral group was 2.496 μg · ml-1, the difference was significant (P0.01) ; The metronidazole content (0.15 1μg · ml-1) in the vaginal drug group was significantly lower than that of the oral drug group (2.144μg · ml-1) (P <0.01). CONCLUSIONS: The results indicate that transvaginal metronidazole in early pregnancy is safer than oral metronidazole.